Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Acceptability of non-drug therapies in older people with orthostatic hypotension: a qualitative study.

Robinson LJ, Pearce RM, Frith J.

BMC Geriatr. 2018 Dec 17;18(1):315. doi: 10.1186/s12877-018-0999-5.

2.

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.

Parrish C, Rahemtulla A, Cavet J, Pearce RM, Kirkland K, Lee J, Cook M, Wilson K, Cook G; Clinical Trials Committee of the British Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1330-4. doi: 10.1016/j.bbmt.2015.03.026. Epub 2015 Apr 3.

3.

A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function.

Dharmagunawardena R, Pearce RM, Thomas G, Kirkland K, Perry J, Apperley JF, Medd P, Wilson KM, Orchard K, Jackson G, Snowden JA, Cook G, Brown JS.

Bone Marrow Transplant. 2014 Nov;49(11):1442-3. doi: 10.1038/bmt.2014.154. Epub 2014 Jul 21. No abstract available.

PMID:
25046217
4.

Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ, Perry J, Snowden JA, Vora AJ, Wynn RT, Russell N, Gibson B, Gilleece M, Milligan D, Veys P, Samarasinghe S, McMullin M, Kirkland K, Cook G; British Society for Blood and Marrow Transplantation, Clinical Trials Committee.

Bone Marrow Transplant. 2014 Jan;49(1):42-8. doi: 10.1038/bmt.2013.115. Epub 2013 Aug 5.

PMID:
23912664
5.

Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21.

6.

Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.

Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, Clark RE, Kazmi M, Abinun M, Jackson GH, Mackinnon S, Russell NH, Cook G; BSBMT Clinical Trials Committee.

Br J Haematol. 2012 Jun;157(6):742-6. doi: 10.1111/j.1365-2141.2012.09122.x. Epub 2012 Apr 26.

PMID:
22533715
7.

Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.

Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL.

Br J Haematol. 2011 Apr;153(2):244-52. doi: 10.1111/j.1365-2141.2011.08615.x. Epub 2011 Mar 8.

PMID:
21382020
8.

Development of an evidence-based patient information medium: empowering newly diagnosed patients with primary biliary cirrhosis.

Pearce RM, Jones DE, Newton JL.

J Vis Commun Med. 2011 Mar;34(1):4-13. doi: 10.3109/17453054.2011.548794.

PMID:
21381930
9.

The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study.

Protheroe RE, Kirkland KE, Pearce RM, Kaminaris K, Bloor A, Potter MN, Nagra S, Gilleece MH, McQuaker IG, Jackson G, Cook G, Marks DI.

Bone Marrow Transplant. 2012 Jan;47(1):88-94. doi: 10.1038/bmt.2011.12. Epub 2011 Feb 28.

PMID:
21358686
10.

Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.

Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI.

Haematologica. 2009 Oct;94(10):1399-406. doi: 10.3324/haematol.2009.008649. Epub 2009 Jul 31.

11.

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH.

Bone Marrow Transplant. 2008 Dec;42(12):783-9. doi: 10.1038/bmt.2008.255. Epub 2008 Aug 25.

PMID:
18724393
12.

Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.

Hill QA, Hill A, Collyns TA, Pearce RM, Cook G.

Bone Marrow Transplant. 2008 Apr;41(8):749-51. doi: 10.1038/sj.bmt.1705974. Epub 2008 Jan 14. No abstract available.

PMID:
18195685
13.

Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.

Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL.

Biol Blood Marrow Transplant. 2007 Jun;13(6):724-33.

14.

Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.

Chantry AD, Snowden JA, Craddock C, Peggs K, Roddie C, Craig JI, Orchard K, Towlson KE, Pearce RM, Marks DI; BSBMT Clinical Trials Committee.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1310-7.

15.

The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.

Cook G, Clark RE, Crawley C, Mackinnon S, Russell N, Thomson K, Pearce RM, Towlson K, Marks DI.

Biol Blood Marrow Transplant. 2006 Mar;12(3):293-300.

16.

Electrocardiographic QT interval prolongation and risk of primary cardiac arrest in diabetic patients.

Whitsel EA, Boyko EJ, Rautaharju PM, Raghunathan TE, Lin D, Pearce RM, Weinmann SA, Siscovick DS.

Diabetes Care. 2005 Aug;28(8):2045-7. No abstract available.

PMID:
16043757
17.

Incidence of out-of-hospital cardiac arrest.

Rea TD, Pearce RM, Raghunathan TE, Lemaitre RN, Sotoodehnia N, Jouven X, Siscovick DS.

Am J Cardiol. 2004 Jun 15;93(12):1455-60.

PMID:
15194012
18.

Digoxin therapy and the risk of primary cardiac arrest in patients with congestive heart failure: effect of mild-moderate renal impairment.

Rea TD, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, Cobb LA, Weinmann S, Anderson GD, Arbogast P, Lin D.

J Clin Epidemiol. 2003 Jul;56(7):646-50.

PMID:
12921933
19.

Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest.

Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, Weinmann SA, Anderson GD, Lin D.

Am J Med. 2002 Dec 15;113(9):711-6.

PMID:
12517359
20.

Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons.

Reiner AP, Rosendaal FR, Reitsma PH, Lemaitre RN, Pearce RM, Friedlander Y, Raghunathan TE, Psaty BM, Siscovick DS.

Am J Cardiol. 2002 Jul 1;90(1):66-8. No abstract available.

PMID:
12088785
21.

Cell membrane trans-fatty acids and the risk of primary cardiac arrest.

Lemaitre RN, King IB, Raghunathan TE, Pearce RM, Weinmann S, Knopp RH, Copass MK, Cobb LA, Siscovick DS.

Circulation. 2002 Feb 12;105(6):697-701.

PMID:
11839624
22.

Platelet glycoprotein IIb polymorphism, traditional risk factors and non-fatal myocardial infarction in young women.

Reiner AP, Schwartz SM, Kumar PN, Rosendaal FR, Pearce RM, Aramaki KM, Psaty BM, Siscovick DS.

Br J Haematol. 2001 Mar;112(3):632-6.

PMID:
11260064
23.

RR interval variation, the QT interval index and risk of primary cardiac arrest among patients without clinically recognized heart disease.

Whitsel EA, Raghunathan TE, Pearce RM, Lin D, Rautaharju PM, Lemaitre R, Siscovick DS.

Eur Heart J. 2001 Jan;22(2):165-73.

PMID:
11161918
24.

The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women.

Frank MB, Reiner AP, Schwartz SM, Kumar PN, Pearce RM, Arbogast PG, Longstreth WT Jr, Rosendaal FR, Psaty BM, Siscovick DS.

Blood. 2001 Feb 15;97(4):875-9.

25.

Genetic variants of platelet glycoprotein receptors and risk of stroke in young women.

Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS.

Stroke. 2000 Jul;31(7):1628-33.

PMID:
10884464
26.

Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry.

Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P, Santini G, Foulard L, Gorin NC.

J Clin Oncol. 1996 Sep;14(9):2454-64.

PMID:
8823323
27.
28.

Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.

Fielding AK, Pearce RM, Goldstone AH.

N Engl J Med. 1995 Sep 14;333(11):729; author reply 730. No abstract available.

PMID:
7637758
29.

Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience.

Rassam SM, Turker A, Powles RL, Smith AG, Newland AC, Erskine JG, Pearce RM, Goldstone AH.

Semin Oncol. 1993 Dec;20(6 Suppl 8):13-9.

PMID:
8290967
30.

Patient progress modelling for small cell lung cancer.

Pearce RM, Gallivan S, Jackson RR.

Eur J Cancer. 1993;29A(5):734-7.

PMID:
8385971
31.

A note on the change in average particle mass during the aging of ammonium chloride smokes.

LANGSTROTH GC, GILLESPIE T, PEARCE RM.

Chem Rev. 1949 Apr;44(2):337-40. No abstract available.

PMID:
18140560
32.

ACUTE LYMPHOCYTIC LEUKAEMIA: RECOVERY AFTER INTRAMUSCULAR INJECTIONS OF HOG SPLEEN.

Pearce RM.

Br Med J. 1930 Aug 23;2(3633):282-3. No abstract available.

33.

THE TREATMENT OF INFLUENZA WITH S.U.P. 36.

Pearce RM.

Br Med J. 1929 Oct 12;2(3588):663-6. No abstract available.

34.
35.

Myeloma with Metastasis to Liver and Spleen.

Pepper OH, Pearce RM.

J Med Res. 1917 Sep;37(1):171-182.1. No abstract available.

36.
37.

REPORT OF THE SUBCOMMITTEE ON PATHOLOGY.

Janeway TC, Opie EL, Wells HG, Pearce RM, Rous P.

Science. 1917 Mar 9;45(1158):233. No abstract available.

PMID:
17782991
38.

THE WORK AND OPPORTUNITIES OF A DEPARTMENT OF RESEARCH MEDICINE IN THE UNIVERSITY.

Pearce RM.

Science. 1916 Jan 14;43(1098):53-63. No abstract available.

PMID:
17768991
40.

STUDIES OF METABOLISM IN THE DOG BEFORE AND AFTER REMOVAL OF THE SPLEEN.

Goldschmidt S, Pearce RM.

J Exp Med. 1915 Sep 1;22(3):319-32.

41.

AN ANALYSIS OF THE MEDICAL GROUP IN CATTELL'S THOUSAND LEADING MEN OF SCIENCE.

Pearce RM.

Science. 1915 Aug 27;42(1078):264-78. No abstract available.

PMID:
17810162
46.

A Study of experimental Nephritis caused by the Salts of tartaric Acid.

Pearce RM, Ringer AI.

J Med Res. 1913 Oct;29(1):57-64. No abstract available.

47.
48.

THE RENAL LESION OF EXPERIMENTAL CANTHARIDIN POISONING.

Pearce RM.

J Exp Med. 1913 May 1;17(5):542-6.

Supplemental Content

Loading ...
Support Center